Elvium Life Sciences’ FOQUEST (methylphenidate hydrochloride controlled release capsules) has been added to the public drug formularies in Ontario and Quebec. These provinces join Saskatchewan, Manitoba, the Northwest Territories, the Non-Insured Health Benefit Plan, and Correctional Service Canada in providing public formulary coverage for FOQUEST for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged six and over.
Elvium Life Sciences’ FOQUEST (methylphenidate hydrochloride controlled release capsules) has been added to the public drug formularies in Ontario and Quebec. These provinces join Saskatchewan, Manitoba, the Northwest Territories, the Non-Insured Health Benefit Plan, and Correctional Service Canada in providing public formulary coverage for FOQUEST for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged six and over.
"Public funding in the two largest provinces in Canada is an important step in ensuring equitable access to ADHD treatments," said Juanita Beaudry, executive director of the centre for ADHD Awareness (CADDAC). "We look forward to all remaining provinces in Canada to quickly follow these reimbursement decisions and providing access to another treatment option for patients."
ADHD is a chronic neurodevelopmental disorder that includes a combination of persistent problems such as difficulty paying attention, hyperactivity, and impulsive behaviour.
